MedPath

Copper

Generic Name
Copper
Brand Names
Paragard T 380a, Vitafol-one, Cuprymina
Drug Type
Small Molecule
Chemical Formula
Cu
CAS Number
7440-50-8
Unique Ingredient Identifier
789U1901C5
Background

Copper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase . Copper is commonly used in contraceptive intrauterine devices (IUD) .

Indication

For use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices .

Associated Conditions
-
Associated Therapies
Emergency Contraception, IUD therapy, Trace Element Deficiency, Dietary supplementation
thepointer.com
·

Pointer investigation reveals disturbing levels of contamination were found at former St

The former GM site in St. Catharines, slated for homes, contained toxic chemicals and heavy metals at alarming levels, detected in 2010 and 2012. Despite this, the site was rezoned for residential use in 2020 without public knowledge of the contamination. A recent release of environmental assessment documents reveals the extent of the contamination, including carcinogens and other hazardous substances, raising concerns for public health and the environment.
globenewswire.com
·

Island Passage Commences Phase 4 Exploration Program

Island Passage Exploration Limited (IPX) commences Phase Four of its mineral exploration program on Bougainville Island, focusing on the Isina exploration license (EL02). The program has identified six prospect-scale areas of interest, including a high-grade gold-silver-copper vein system. IPX aims to earn a 70% interest in the tenement from Isina Resource Holdings Limited (IRHL).
urologytimes.com
·

Enrollment goal met in phase 3 SOLAR-RECUR trial

The SOLAR-RECUR trial (NCT06235099) evaluating Cu 64 PSMA I&T PET/CT in men with suspected prostate cancer recurrence met its enrollment target early. SOLAR-STAGE, another phase 3 trial, continues enrollment for staging newly diagnosed prostate cancer. Both trials aim to assess diagnostic performance and are expected to complete by July 2025.
globenewswire.com
·

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

Curium completed enrollment for Phase 3 SOLAR-RECUR trial evaluating Cu 64 PSMA I&T PET/CT in prostate cancer recurrence. SOLAR-STAGE trial for staging continues enrollment in the U.S. and expands to Europe.
biospace.com
·

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech announces FDA approval for Emrosi to treat rosacea and potential approval for cosibelimab for cutaneous squamous cell carcinoma, with financial results and recent corporate highlights for Q3 2024.
pharmacytimes.com
·

Incorporating Hormonal Contraceptive Prescribing Benefits Patients, Pharmacies

Pharmacists, especially in maternal health deserts, are crucial for women's health, particularly in states like Arkansas with high teen pregnancies and maternal mortality. 23 states allow pharmacist contraceptive prescribing, with Arkansas permitting only hormonal oral contraception. Effective methods include implants and IUDs, while less effective ones are fertility awareness and condoms. Reimbursement remains a significant barrier, with $75 for counseling being standard in some areas.
investingnews.com
·

Horizon and Poseidon Merging to Fast-Track the Creation of a New WA Mid-Cap Gold Producer

Horizon Minerals and Poseidon Nickel merge to consolidate assets in WA Goldfields, aiming for sustainable gold production using Poseidon's Black Swan infrastructure. The merger includes a $14 million placement and aims to fast-track gold production with a 5-year mine plan. The combined entity targets 100kozpa standalone production and enhanced market relevance.
browndailyherald.com
·

Brown to receive $12 million to research alcohol and substance abuse

Alexander Sokolovsky’s research on polysubstance use at Brown’s CADRE, funded by a $12.3 million federal grant, aims to understand substance use decisions and their consequences, using day-by-day evaluations and biosensors to study cannabis’s impact on depression. CADRE, a NIH-recognized COBRE, seeks to develop a self-sustaining research facility in Rhode Island, emphasizing community engagement and collaborative research to address substance use and chronic disease.
corsicanadailysun.com
·

Faraday Copper Intersects 1.31% Copper over 22.65 Metres within 50.20

Faraday Copper Corp. reports drill hole FCD-24-074 intersected 22.65 m at 1.31% copper within 50.20 m at 0.74% copper, delineating 400 m of mineralization at the Banjo breccia in Arizona's Copper Creek Project. The hole suggests significant copper concentration through supergene enrichment, with ongoing drilling focused on near-surface mineralization outside the resource area.
© Copyright 2025. All Rights Reserved by MedPath